NLRP3 and metabolic dysfunction-associated steatotic liver disease: The NAD+/SIRT2 pathway is a crucial mediator of silybin blocking NLRP3 inflammasome activation in NAFLD, and the anti-inflammatory effects of silybin were impeded by silencing SIRT2 or the SIRT2 inhibitor AGK2.